Bayer: halts late-stage study on embolic stroke.
(CercleFinance.com) - Bayer said on Friday that it has halted early a new study on anticoagulant Xarelto as it indicated comparable efficacy between treatment arms.
The phase III trial evaluating Xarelto compared to aspirin in patients with embolic stroke of undetermined source (ESUS) indicated at interim no efficacy improvement over low dose aspirin, the German drugs and chemicals group said.
The study also showed very little chance of overall benefit if completed, Bayer said.
As a reminder, Xarelto is already approved for seven indications, across venous and arterial thromboembolic conditions.
Despite the news, Bayer shares are actually up 0.3% this morning in Frankfurt.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The phase III trial evaluating Xarelto compared to aspirin in patients with embolic stroke of undetermined source (ESUS) indicated at interim no efficacy improvement over low dose aspirin, the German drugs and chemicals group said.
The study also showed very little chance of overall benefit if completed, Bayer said.
As a reminder, Xarelto is already approved for seven indications, across venous and arterial thromboembolic conditions.
Despite the news, Bayer shares are actually up 0.3% this morning in Frankfurt.
Copyright (c) 2017 CercleFinance.com. All rights reserved.